[go: up one dir, main page]

WO2006027545A3 - Method - Google Patents

Method Download PDF

Info

Publication number
WO2006027545A3
WO2006027545A3 PCT/GB2005/003206 GB2005003206W WO2006027545A3 WO 2006027545 A3 WO2006027545 A3 WO 2006027545A3 GB 2005003206 W GB2005003206 W GB 2005003206W WO 2006027545 A3 WO2006027545 A3 WO 2006027545A3
Authority
WO
WIPO (PCT)
Prior art keywords
mtor
stem cell
activity
enable
renew
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/003206
Other languages
French (fr)
Other versions
WO2006027545A2 (en
Inventor
Sai Kiang Lim
Jian Wen Que
Oakley Reida Menshawe El
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of WO2006027545A2 publication Critical patent/WO2006027545A2/en
Publication of WO2006027545A3 publication Critical patent/WO2006027545A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0604—Whole embryos; Culture medium therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

We provide a method comprising modulating the activity of mTOR in a stem cell, preferably increasing the activity of mTOR to enable a stem cell to self-renew, or decreasing it to enable a stem cell to differentiate. The stem cell may be exposed to an agonist of mTOR for the former, preferably phosphatidic acid, or an antagonist of mTOR for the latter, preferably 1-butanol or rapamycin or a derivative thereof.
PCT/GB2005/003206 2004-09-10 2005-08-17 Method Ceased WO2006027545A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60921604P 2004-09-10 2004-09-10
US60/609,216 2004-09-10

Publications (2)

Publication Number Publication Date
WO2006027545A2 WO2006027545A2 (en) 2006-03-16
WO2006027545A3 true WO2006027545A3 (en) 2006-04-27

Family

ID=35613852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003206 Ceased WO2006027545A2 (en) 2004-09-10 2005-08-17 Method

Country Status (1)

Country Link
WO (1) WO2006027545A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106244522A (en) * 2016-08-12 2016-12-21 浙江译美生物科技有限公司 A kind of stem cell cultivating system and cultural method thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646990B2 (en) 2007-04-23 2014-12-24 ストワーズ インスティテュート フォー メディカル リサーチ Methods and compositions for stem cell self-renewal
KR100937456B1 (en) * 2007-08-01 2010-01-19 한국생명공학연구원 How to differentiate human embryonic stem cells into osteoblasts
WO2013081554A1 (en) 2011-11-30 2013-06-06 Agency For Science, Technology And Research Gm1 ganglioside to annexin v microparticle polypeptide ratio for biological monitoring
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN106987555B (en) * 2016-01-20 2021-10-19 中国科学院上海营养与健康研究所 Small molecule compound composition for efficiently inducing differentiation of human pluripotent stem cells into cardiomyocytes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080975A1 (en) * 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080975A1 (en) * 2001-04-06 2002-10-17 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAS A V ET AL: "C - Kit receptor plays an important role in the maintenance of the adult neural stem cells: interaction with Notch signaling.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 452.12 URL - http://sf, XP009060950 *
FENG L X ET AL: "Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 18 AUG 2000, vol. 275, no. 33, 18 August 2000 (2000-08-18), pages 25572 - 25576, XP002365724, ISSN: 0021-9258 *
MITA MONICA M ET AL: "The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.", CANCER BIOLOGY & THERAPY. 2003 JUL-AUG, vol. 2, no. 4 Suppl 1, July 2003 (2003-07-01), pages S169 - S177, XP009060677, ISSN: 1538-4047 *
MURAKAMI MIREI ET AL: "mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells.", MOLECULAR AND CELLULAR BIOLOGY. AUG 2004, vol. 24, no. 15, August 2004 (2004-08-01), pages 6710 - 6718, XP002365723, ISSN: 0270-7306 *
RAJAN PRITHI ET AL: "BMPs signal alternately through a SMAD or FRAP-STAT pathway to regulate fate choice in CNS stem cells.", THE JOURNAL OF CELL BIOLOGY. 9 JUN 2003, vol. 161, no. 5, 9 June 2003 (2003-06-09), pages 911 - 921, XP002365725, ISSN: 0021-9525 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106244522A (en) * 2016-08-12 2016-12-21 浙江译美生物科技有限公司 A kind of stem cell cultivating system and cultural method thereof

Also Published As

Publication number Publication date
WO2006027545A2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
WO2007101225A3 (en) Methods to identify inhibitors of the unfolded protein response
EP2270008B8 (en) 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors
WO2007007201A8 (en) Systems and methods for semantic knowledge assessment, instruction, and acquisition
WO2006083390A3 (en) Eotaxin-3 in eosinophilic esophagitis
IL184901A0 (en) 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors
AU2003218844A1 (en) Multiple model systems and methods for testing electrochemical systems
LT2057156T (en) 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
AP2006003705A0 (en) Quinoline derivatives for use as mycobacterial inhibitors
ZA200706672B (en) 2,4-Diamino-pyridopyrimidine derivatives and their use as mTOR inhibitors
GB2441091B (en) Methods and systems for putting analysis
EP1965633A4 (en) Method and arrangement for animal management
WO2006027545A3 (en) Method
WO2007007200A8 (en) Method and device for automatic event detection and report generation
WO2006012351A3 (en) Markers for brain damage
WO2006099486A3 (en) Method and compounds for detecting protein-protein and protein-nucleic acid interactions
WO2010039899A3 (en) Method for monitoring intracellular tyrosine phosphatase activity
WO2006089009A8 (en) Methods and compositions for the treatment of lipid-associated disorders
EP1752563B8 (en) Masking techniques for electrochemical stripping
TNSN07428A1 (en) Method
WO2006069142A3 (en) Methods for determining cellular response to stimuli
WO2006076580A3 (en) A method of modulating t cell functioning
HK1118123A (en) Systems and methods for delivering parameters to automated security order execution systems
AU2011226906B2 (en) Systems and methods for thermally profiling radiofrequency electrodes
HK1119477A (en) Systems and methods for semantic knowledge assessment, instruction, and acquisition
HK1113972A (en) Compositions and methods for cell killing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase